Misplaced Pages

Vitiligo
Non-segmental vitiligo of the hand
Pronunciation	/ˌvɪtɪˈlaɪɡoʊ/ vit-il-eye-goh
Specialty	Dermatology Immunology
Symptoms	Patches of white skin
Usual onset	Childhood, young adult
Duration	Long term
Causes	Unknown
Risk factors	Family history, other autoimmune diseases
Diagnostic method	Tissue biopsy
Treatment	Sunscreen, makeup, topical corticosteroids, phototherapy
Frequency	0.1-2.1%

Vitiligo (/ˌvɪtɪˈlaɪɡoʊ/, vit-il-eye-goh) is a chronic autoimmune disorder that causes patches of skin to lose pigment or color. The cause of vitiligo is unknown, but it may be related to immune system changes, genetic factors, stress, or sun exposure. Treatment options include topical medications, light therapy, surgery and cosmetics. The condition can show up on any skin type as a light peachy color and can appear on any place on the body in all sizes. The spots on the skin known as vitiligo are also able to “change” as spots lose and regain pigment; they will stay in relatively the same areas but can move over time and some big patches can move through the years but never disappear overnight.

Signs and symptoms

The only sign of vitiligo is the presence of pale patchy areas of depigmented skin which tend to occur on the extremities. Some people may experience itching before a new patch appears. The patches are initially small, but often grow and change shape. When skin lesions occur, they are most prominent on the face, hands and wrists. The loss of skin pigmentation is particularly noticeable around body orifices, such as the mouth, eyes, nostrils, genitalia and umbilicus. Some lesions have increased skin pigment around the edges. Those affected by vitiligo who are stigmatized for their condition may experience depression and similar mood disorders.

• Vitiligo on lighter skin
• Non-segmental vitiligo on dark skin
• Non-segmental vitiligo of the eyelids

Causes

Although multiple hypotheses have been suggested as potential triggers that cause vitiligo, studies strongly imply that changes in the immune system are responsible for the condition. Vitiligo has been proposed to be a multifactorial disease with genetic susceptibility and environmental factors both thought to play a role. It is hypothesized that damaging environmental factors can disrupt redox reactions necessary for protein folding, so skin cells may initiate the unfolded protein response which releases cytokines, thus mounting an immune response

The National Institutes of Health states that sometimes an event, like a sunburn, emotional distress, or exposure to a chemical, can trigger or exacerbate the condition, Skin depigmentation in particular areas in vitiligo can also be triggered by mechanical trauma: this is an example of the Koebner phenomenom. Unlike in other skin diseases, this can be caused by daily activities, especially chronic friction on particular areas of the body.

Immune

Melanin is the pigment that gives skin its color; it is produced by skin cells called melanocytes.

Variations in genes that are part of the immune system or part of melanocytes have both been associated with vitiligo. It is also thought to be caused by the immune system attacking and destroying the melanocytes of the skin. A genome wide association study found approximately 36 independent susceptibility loci for generalized vitiligo.

The TYR gene encodes the protein tyrosinase, which is not a component of the immune system but is an enzyme of the melanocyte that catalyzes melanin biosynthesis, and a major autoantigen in generalized vitiligo.

Autoimmune associations

Vitiligo is sometimes associated with autoimmune and inflammatory diseases such as Hashimoto's thyroiditis, scleroderma, rheumatoid arthritis, type 1 diabetes mellitus, psoriasis, Addison's disease, pernicious anemia, alopecia areata, systemic lupus erythematosus, and celiac disease.

Among the inflammatory products of NLRP1 are caspase 1 and caspase 7, which activate the inflammatory cytokine interleukin-1β. Interleukin-1β and interleukin-18 are expressed at high levels in people with vitiligo. In one of the mutations, the amino acid leucine in the NALP1 protein was replaced by histidine (Leu155 → His). The original protein and sequence is highly conserved in evolution, and is found in humans, chimpanzee, rhesus monkey, and the bush baby. Addison's disease (typically an autoimmune destruction of the adrenal glands) may also be seen in individuals with vitiligo.

Oxidative stress

Numerous whole-exome sequencing studies have demonstrated that vitiligo is associated with polymorphisms in genes involved in the response to oxidative stress such as CAT, SOD1, SOD2, SOD3, NFE2L2, HMOX1, GST-M1 or GST-T1 supporting the association of elevated levels of reactive oxygen species in melanocytes with the induction of an auto-immune response.

Thus, diseases presenting with altered mitochondrial function such as MELAS, Vogt-Koyanagi-Harada syndrome, Kabuki syndrome are associated with increased risk of vitiligo.

In line with these observations, genetic alterations in mitochondrial DNA (mtDNA) of melanocytes associated with altered mitochondrial function lead to a release of mtDNA that can be detected in the skin of vitiligo patients. This mtDNA can be sensed by the cGAS-STING pathway resulting in pro-inflammatory cytokine and chemokines production promoting the recruitment of cytotoxic CD8+ T cells. The use of mitochondrial antioxidants, NRF2 inhibitors, and TBK1 inhibitors is emerging as potential therapeutic options to block this cascade of events.

Diagnosis

An ultraviolet light can be used in the early phase of this disease for identification and to determine the effectiveness of treatment. Using a Wood's light, skin will change colour (fluoresce) when it is affected by certain bacteria, fungi, and changes to pigmentation of the skin.

Classification

Classification attempts to quantify vitiligo have been analyzed as being somewhat inconsistent, while recent consensus has agreed to a system of segmental vitiligo (SV) and non-segmental vitiligo (NSV). NSV is the most common type of vitiligo.

Non-segmental

In non-segmental vitiligo (NSV), there is usually some form of symmetry in the location of the patches of depigmentation. New patches also appear over time and can be generalized over large portions of the body or localized to a particular area. Extreme cases of vitiligo, to the extent that little pigmented skin remains, are referred to as vitiligo universalis. NSV can come about at any age (unlike segmental vitiligo, which is far more prevalent in teenage years).

Classes of non-segmental vitiligo include the following:

• Generalized vitiligo: the most common pattern, wide and randomly distributed areas of depigmentation
• Universal vitiligo: depigmentation encompasses most of the body
• Focal vitiligo: one or a few scattered macules in one area, most common in children
• Acrofacial vitiligo: fingers and periorificial areas
• Mucosal vitiligo: depigmentation of only the mucous membranes

Segmental

Segmental vitiligo (SV) differs in appearance, cause, and frequency of associated illnesses. Its treatment is different from that of NSV. It tends to affect areas of skin that are associated with dorsal roots from the spinal cord and is most often unilateral. It is much more stable/static in its course and its association with autoimmune diseases appears to be weaker than that of generalized vitiligo. SV does not improve with topical therapies or UV light; however, surgical treatments such as cellular grafting can be effective.

Differential diagnosis

Chemical leukoderma is a similar condition due to multiple exposures to chemicals. Vitiligo however is a risk factor. Triggers may include inflammatory skin conditions, burns, intralesional steroid injections, and abrasions.

Other conditions with similar symptoms include the following:

• albinism
• halo nevus
• idiopathic guttate hypomelanosis (white sunspots)
• piebaldism
• pityriasis alba
• postinflammatory hypopigmentation
• primary adrenal insufficiency
• progressive macular hypomelanosis
• tinea versicolor
• tuberculoid leprosy

Treatment

There is no cure for vitiligo but several treatment options are available. The best evidence is for applied steroids and ultraviolet light in combination with creams. Due to the higher risks of skin cancer, the United Kingdom's National Health Service suggests phototherapy be used only if primary treatments are ineffective. Lesions located on the hands, feet, and joints are the most difficult to repigment; those on the face are easiest to return to the natural skin color as the skin is thinner.

Immune mediators

Topical preparations of immune-suppressing medications including glucocorticoids (such as 0.05% clobetasol or 0.10% betamethasone) and calcineurin inhibitors (such as tacrolimus or pimecrolimus) are considered to be first-line vitiligo treatments.

In July 2022, ruxolitinib cream (sold under the brand name Opzelura) was approved for medical use in the United States for the treatment of vitiligo.

Phototherapy

Phototherapy is considered a second-line treatment for vitiligo. Exposing the skin to light from UVB lamps is the most common treatment for vitiligo. The treatments can be done at home with a UVB lamp or in a clinic. The exposure time is managed so that the skin does not suffer overexposure. Treatment can take a few weeks if the spots are on the neck and face and if they existed not more than 3 years. If the spots are on the hands and legs and have been there for more than 3 years, it can take a few months. Phototherapy sessions are done 2–3 times a week. Spots on a large area of the body may require full-body treatment in a clinic or hospital. UVB broadband and narrowband lamps can be used, but narrowband ultraviolet peaked around 311 nm is the choice. It has been constitutively reported that a combination of UVB phototherapy with other topical treatments improves re-pigmentation. However, some people with vitiligo may not see any changes to skin or re-pigmentation occurring. A serious potential side effect involves the risk of developing skin cancer, the same risk as an overexposure to natural sunlight.

Ultraviolet light (UVA) treatments are normally carried out in a hospital clinic. Psoralen and ultraviolet A light (PUVA) treatment involves taking a drug that increases the skin's sensitivity to ultraviolet light and then exposing the skin to high doses of UVA light. Treatment is required twice a week for 6–12 months or longer. Because of the high doses of UVA and psoralen, PUVA may cause side effects such as sunburn-type reactions or skin freckling.

Narrowband ultraviolet B (NBUVB) phototherapy lacks the side effects caused by psoralens and is as effective as PUVA. As with PUVA, treatment is carried out twice weekly in a clinic or every day at home, and there is no need to use psoralen. Longer treatment is often recommended, and at least 6 months may be required for effects to phototherapy. NBUVB phototherapy appears better than PUVA therapy with the most effective response on the face and neck.

With respect to improved repigmentation: topical calcineurin inhibitors plus phototherapy are better than phototherapy alone, hydrocortisone plus laser light is better than laser light alone, ginkgo biloba is better than placebo, and oral mini-pulse of prednisolone (OMP) plus NB-UVB is better than OMP alone.

Skin camouflage

In mild cases, vitiligo patches can be hidden with makeup or other cosmetic camouflage solutions. If the affected person is pale-skinned, the patches can be made less visible by avoiding tanning of unaffected skin.

Depigmenting

In cases of extensive vitiligo the option to depigment the unaffected skin with topical drugs like monobenzone, mequinol, or hydroquinone may be considered to render the skin an even color. The removal of all the skin pigment with monobenzone is permanent and vigorous. Sun safety must be adhered to for life to avoid severe sunburn and melanomas. Depigmentation takes about a year to complete.

History

Descriptions of a disease believed to be vitiligo date back to a passage in the medical text Ebers Papyrus c. 1500 BC in ancient Egypt. Also, the Hebrew word "Tzaraath" from the Old Testament book of Leviticus dating to 1280 BC (or 1312 BC) described a group of skin diseases associated with white spots, and a subsequent translation to Greek led to continued conflation of those with vitiligo with leprosy and spiritual uncleanliness.

Medical sources in the ancient world such as Hippocrates often did not differentiate between vitiligo and leprosy, often grouping these diseases together. The name "vitiligo" was first used by the Roman physician Aulus Cornelius Celsus in his classic medical text De Medicina.

The term vitiligo is believed to be derived from "vitium", meaning "defect" or "blemish".

Society and culture

The change in appearance caused by vitiligo can affect a person's emotional and psychological well-being and may create difficulty in becoming or remaining employed, particularly if vitiligo develops on visible areas of the body, such as the face, hands or arms. Participating in a vitiligo support group may improve social coping skills and emotional resilience.

Notable people with vitiligo

Notable cases include American pop singer Michael Jackson, Canadian fashion model Winnie Harlow, New Zealand singer-songwriter Kimbra, American actor David Dastmalchian and Argentine musician Charly García. Professional wrestler Bryan Danielson and French actor Michaël Youn are also affected, as is former French Prime Minister Édouard Philippe, Miss Universe Egypt 2024 Logina Salah, former Roman Catholic priest, Governor of Pampanga and TV host Eddie Panlilio, and model and former Miss Colombia 2007 Taliana Vargas.

In popular culture

The Adult Swim animated sitcom The Boondocks satirizes the idea of vitiligo in Uncle Ruckus, one of the show's characters. Ruckus, who is black, frequently claims to be white, often stating that he has "Re-vitiligo, the opposite of what Michael Jackson had." He frequently uses this argument to maintain that he is actually white, leading him to commit delusional and racist antics in nearly every episode.

Research

As of July 2013, afamelanotide is in phase II and III clinical trials for vitiligo and other skin diseases.

A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo.

In October 1992, a scientific report was published of successfully transplanting melanocytes to vitiligo-affected areas, effectively repigmenting the region. The procedure involved taking a thin layer of pigmented skin from the person's gluteal region. Melanocytes were then separated out to a cellular suspension that was expanded in culture. The area to be treated was then denuded with a dermabrader and the melanocytes graft applied. Between 70 and 85 percent of people with vitiligo experienced nearly complete repigmentation of their skin. The longevity of the repigmentation differed from person to person.

Current research suggests that the Janus kinase/signal transducer and activator of the transcription pathway (JAK/STAT pathway) plays a crucial role in the loss of epidermal melanocytes. This pathway is activated by CXCR3+ CD8+ T cells, creating a positive feedback loop with interferon-gamma (IFN-γ) chemokines from keratinocytes, potentially contributing to vitiligo. JAK inhibitors like ruxolitinib show promise in targeting the IFN-γ-chemokine signaling axis implicated in vitiligo pathogenesis, and improving nonsegmental vitiligo.

References

1. ^ James WD, Elston D, Treat JR, Rosenbach MA, Neuhaus I (2020). "36. Disturbances of pigmentation". Andrews' Diseases of the Skin: Clinical Dermatology (13th ed.). Edinburgh: Elsevier. pp. 871–874. ISBN 978-0-323-54753-6.
2. ^ Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (July 2015). "Vitiligo". Lancet. 386 (9988): 74–84. doi:10.1016/s0140-6736(14)60763-7. PMID 25596811. S2CID 208791128.
3. ^ "Questions and Answers about Vitiligo". NIAMS. June 2014. Archived from the original on 21 August 2016. Retrieved 11 August 2016.
4. Zhang Y, Cai Y, Shi M, Jiang S, Cui S (2016). "The Prevalence of Vitiligo: A Meta-Analysis". PLOS ONE. 11 (9): e0163806. Bibcode:2016PLoSO..1163806Z. doi:10.1371/journal.pone.0163806.
5. "Vitiligo - Symptoms and causes". Mayo Clinic. Retrieved 5 May 2023.
6. ^ "Vitiligo Symptoms, Treatment & Causes". NIAMS. 12 April 2017. Retrieved 5 May 2023.
7. ^ National Institute of Arthritis and Musculoskeletal and Skin Diseases (March 2007). "What Is Vitiligo? Fast Facts: An Easy-to-Read Series of Publications for the Public Additional". Archived from the original on 15 July 2010. Retrieved 18 July 2010.
8. ^ Halder RM, Taliaferro S (2007). "72. Vitiligo". In Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D (eds.). Fitzpatrick's dermatology in general medicine (7th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-146690-5. OCLC 154751587.
9. ^ Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, et al. (February 2015). "Interventions for vitiligo". The Cochrane Database of Systematic Reviews. 2015 (2): CD003263. doi:10.1002/14651858.CD003263.pub5. PMC 10887429. PMID 25710794.
10. Halder RM, Chappell JL (June 2009). "Vitiligo update". Seminars in Cutaneous Medicine and Surgery. 28 (2): 86–92. doi:10.1016/j.sder.2009.04.008 (inactive 1 November 2024). PMID 19608058.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
11. ^ Huggins RH, Schwartz RA, Janniger C (December 2005). "Vitiligo" (PDF). Acta Dermatovenerologica Alpina, Pannonica, et Adriatica. 14 (4): 137–42, 144–45. PMID 16435042. Archived (PDF) from the original on 10 December 2006.
12. Picardi A, Pasquini P, Cattaruzza MS, Gaetano P, Melchi CF, Baliva G, et al. (2003). "Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study". Psychotherapy and Psychosomatics. 72 (3): 150–158. doi:10.1159/000069731. PMID 12707482. S2CID 22105282.
13. Ongenae K, Van Geel N, Naeyaert JM (April 2003). "Evidence for an autoimmune pathogenesis of vitiligo". Pigment Cell Research. 16 (2): 90–100. doi:10.1034/j.1600-0749.2003.00023.x. PMID 12622785.
14. Baldini E, Odorisio T, Sorrenti S, Catania A, Tartaglia F, Carbotta G, et al. (27 October 2017). "Vitiligo and Autoimmune Thyroid Disorders". Frontiers in Endocrinology. 8 (290): 290. doi:10.3389/fendo.2017.00290. PMC 5663726. PMID 29163360.
15. Chang WL, Lee WR, Kuo YC, Huang YH (14 December 2021). "Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention". Frontiers in Cell and Developmental Biology. 9 (797026): 797026. doi:10.3389/fcell.2021.797026. PMC 8712646. PMID 34970551.
16. "Questions and Answers about Vitiligo". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 30 October 2022. Archived from the original on 8 August 2007. Retrieved 29 June 2024.
17. ^ Zhang Y, Ding X, Wang F, Li M, Du J (February 2023). "Clinical significance of Koebner's phenomenon in vitiligo: a hospital-based epidemiological investigation from China". Chinese Medical Journal. 136 (4): 502–504. doi:10.1097/CM9.0000000000002431. PMC 10106213. PMID 36580639.
18. Mayo Clinic Staff (15 May 2014). "Vitiligo Causes". Mayoclinic. Archived from the original on 30 April 2015. Retrieved 22 April 2015.
19. Spritz RA (May 2013). "Modern vitiligo genetics sheds new light on an ancient disease". The Journal of Dermatology. 40 (5): 310–318. doi:10.1111/1346-8138.12147. PMC 3783942. PMID 23668538.
20. Van Driessche F, Silverberg N (August 2015). "Current Management of Pediatric Vitiligo". Paediatric Drugs (Review). 17 (4): 303–313. doi:10.1007/s40272-015-0135-3. PMID 26022363. S2CID 20038695.
21. Lamkanfi M, Vande Walle L, Kanneganti TD (September 2011). "Deregulated inflammasome signaling in disease". Immunological Reviews (Review). 243 (1): 163–173. doi:10.1111/j.1600-065X.2011.01042.x. PMC 3170132. PMID 21884175.
22. Gregersen PK (March 2007). "Modern genetics, ancient defenses, and potential therapies". The New England Journal of Medicine. 356 (12): 1263–1266. doi:10.1056/NEJMe078017. PMID 17377166.
23. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. (March 2007). "NALP1 in vitiligo-associated multiple autoimmune disease" (PDF). The New England Journal of Medicine. 356 (12): 1216–1225. doi:10.1056/NEJMoa061592. PMID 17377159. Archived (PDF) from the original on 6 March 2020. Retrieved 16 December 2019.
24. Chiarella P (22 October 2019). "Vitiligo susceptibility at workplace and in daily life: the contribution of oxidative stress gene polymorphisms". Biomedical Dermatology. 3 (1): 5. doi:10.1186/s41702-019-0043-1. ISSN 2398-8460.
25. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (July 2015). "Vitiligo". Lancet. 386 (9988): 74–84. doi:10.1016/S0140-6736(14)60763-7. PMID 25596811.
26. Karvonen SL, Haapasaari KM, Kallioinen M, Oikarinen A, Hassinen IE, Majamaa K (April 1999). "Increased prevalence of vitiligo, but no evidence of premature ageing, in the skin of patients with bp 3243 mutation in mitochondrial DNA in the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS)". The British Journal of Dermatology. 140 (4): 634–639. doi:10.1046/j.1365-2133.1999.02761.x. PMID 10233312.
27. Liang L, Tan X, Zhou Q, Tian Y, Kijlstra A, Yang P (19 August 2015). "TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species". Current Molecular Medicine. 15 (6): 529–542. doi:10.2174/1566524015666150731095611. PMID 26238371.
28. Margot H, Boursier G, Duflos C, Sanchez E, Amiel J, Andrau JC, et al. (January 2020). "Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals". Genetics in Medicine. 22 (1): 181–188. doi:10.1038/s41436-019-0623-x. PMID 31363182.
29. ^ Sant'Anna-Silva AC, Botton T, Rossi A, Dobner J, Bzioueche H, Thach N, et al. (August 2024). "Vitiligo auto-immune response upon oxidative stress-related mitochondrial DNA release opens up new therapeutic strategies". Clinical and Translational Medicine. 14 (8): e1810. doi:10.1002/ctm2.1810. PMC 11306283. PMID 39113238.
30. Bzioueche H, Simonyté Sjödin K, West CE, Khemis A, Rocchi S, Passeron T, et al. (September 2021). "Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes". The Journal of Investigative Dermatology. 141 (9): 2280–2290. doi:10.1016/j.jid.2021.01.036. PMID 33771527.
31. Wang YJ, Chang CC, Cheng KL (December 2017). "Wood's lamp for vitiligo disease stability and early recognition of initiative pigmentation after epidermal grafting". International Wound Journal. 14 (6): 1391–1394. doi:10.1111/iwj.12800. PMC 7949874. PMID 28799192. S2CID 205222684.
32. Al Aboud DM, Gossman W (2019). "Woods Light (Woods Lamp)". StatPearls. StatPearls Publishing. PMID 30725878.
33. Picardo M, Taïeb A, eds. (2009). "Introduction". Vitiligo. Berlin: Springer. ISBN 978-3-540-69360-4.
34. ^ Halder RM (2007). "Vitiligo". In Fitzpatrick TB, Wolff K (eds.). Fitzpatrick's Dermatology in General Medicine (7th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-146690-5.
35. ^ van Geel N, Mollet I, Brochez L, Dutré M, De Schepper S, Verhaeghe E, et al. (February 2012). "New insights in segmental vitiligo: case report and review of theories". The British Journal of Dermatology. 166 (2): 240–246. doi:10.1111/j.1365-2133.2011.10650.x. PMID 21936857. S2CID 32746282.
36. Whitton ME, Ashcroft DM, González U (October 2008). "Therapeutic interventions for vitiligo". Journal of the American Academy of Dermatology. 59 (4): 713–717. doi:10.1016/j.jaad.2008.06.023. PMID 18793940.
37. ^ Anon. "Vitiligo -Treatment". Patient UK. NHS. Archived from the original on 6 June 2013. Retrieved 3 June 2013.
38. "Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo". Incyte. 19 July 2022. Archived from the original on 19 July 2022. Retrieved 19 July 2022 – via Business Wire.
39. Scherschun L, Kim JJ, Lim HW (June 2001). "Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo". Journal of the American Academy of Dermatology. 44 (6): 999–1003. doi:10.1067/mjd.2001.114752. PMID 11369913. S2CID 17431219.
40. Don P, Iuga A, Dacko A, Hardick K (January 2006). "Treatment of vitiligo with broadband ultraviolet B and vitamins". International Journal of Dermatology. 45 (1): 63–65. doi:10.1111/j.1365-4632.2005.02447.x. PMID 16426381. S2CID 454415.
41. ^ Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. (July 2017). "Phototherapy for Vitiligo: A Systematic Review and Meta-analysis". JAMA Dermatology. 153 (7): 666–674. doi:10.1001/jamadermatol.2017.0002. PMC 5817459. PMID 28355423.
42. Bae JM, Hong BY, Lee JH, Lee JH, Kim GM (May 2016). "The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs)". Journal of the American Academy of Dermatology. 74 (5): 907–915. doi:10.1016/j.jaad.2015.11.044. PMID 26785803.
43. ^ Gauthier Y, Benzekri L (2009). "Historical Aspects". In Picardo M, Taïeb A (eds.). Vitiligo (Online-Ausg. ed.). Berlin: Springer. ISBN 978-3-540-69360-4.
44. Kurzweil A (2008). The Torah For Dummies (PDF). For Dummies. p. 11. ISBN 978-0-470-28306-6. Archived (PDF) from the original on 22 June 2020. Retrieved 19 August 2010.
45. Spiro K. "History Crash Course #36: Timeline: From Abraham to Destruction of the Temple". Aish.com. Archived from the original on 20 July 2014. Retrieved 19 August 2010.
46. Chaturvedi SK, Singh G, Gupta N (October 2005). "Stigma experience in skin disorders: an Indian perspective". Dermatologic Clinics. 23 (4): 635–642. doi:10.1016/j.det.2005.05.007. PMID 16112439.
47. Vogel J (17 March 2018). "Black and White: how Dangerous kicked off Michael Jackson's race paradox". The Guardian. Archived from the original on 17 March 2018. Retrieved 14 September 2019.
48. "Winnie Harlow: Canadian Model With Rare Skin Condition Lands 2 Major Campaigns". Complex. Archived from the original on 23 October 2020. Retrieved 17 February 2020.
49. Deahl D (4 May 2018). "Kimbra on the tech she carries everywhere". The Verge. Retrieved 23 November 2022.
50. @WWEDanielBryan (30 July 2011). "@tarynlove77 It's vitiligo, not any artificial patch, which is an autoimmune disease you can look up on Misplaced Pages" (Tweet) – via Twitter.
51. Prisma MP (11 June 2018). "Michaël Youn : l'étonnante maladie génétique dont il est atteint… au niveau du pénis - Voici". Voici.fr (in French). Archived from the original on 25 September 2021. Retrieved 25 September 2021.
52. Match P (26 June 2020). "Dans les coulisses de la campagne d'Edouard Philippe au Havre". parismatch.com (in French). Archived from the original on 14 September 2021. Retrieved 25 September 2021.
53. Bi H (6 October 2024). "Người phụ nữ một con với làn da bạch biến sẽ đối đầu với Kỳ Duyên tại Miss Universe". Saostar (in Vietnamese). Retrieved 7 October 2024.
54. "Taliana Vargas muestra nuevas marcas de vitiligo en su piel". eltiempo.com. 4 June 2021. Retrieved 12 December 2022.
55. "Taliana Vargas explicó cómo va el tratamiento para su problema de piel". infobae.com. 26 October 2022. Retrieved 12 December 2022.
56. Marsh K (15 March 2023). "Why I use 'The Boondocks' TV cartoon show to teach a course about race". The Conversation. Retrieved 8 January 2024.
57. Fabrikant J, Touloei K, Brown SM (July 2013). "A review and update on melanocyte stimulating hormone therapy: afamelanotide". Journal of Drugs in Dermatology. 12 (7): 775–779. PMID 23884489.
58. "For vitiligo patient, arthritis drug restores skin color". 24 June 2015. Archived from the original on 22 July 2015.
59. Olsson MJ, Juhlin L (October 1992). "Melanocyte transplantation in vitiligo". Lancet. 340 (8825): 981. doi:10.1016/0140-6736(92)92875-G. PMID 1357390. S2CID 19599682.
60. Olsson MJ, Juhlin L (November 2002). "Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension". The British Journal of Dermatology. 147 (5): 893–904. doi:10.1046/j.1365-2133.2002.04837.x. PMID 12410698. S2CID 42396825.
61. ^ Qi F, Liu F, Gao L (2021). "Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review". Frontiers in Immunology. 12: 790125. doi:10.3389/fimmu.2021.790125. PMC 8636851. PMID 34868078.
62. Clinical trial number NCT04052425 for "Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)" at ClinicalTrials.gov
63. Clinical trial number NCT04057573 for "Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)" at ClinicalTrials.gov

External links

• Questions and Answers about Vitiligo – US National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Autoimmune diseases
• Disturbances of human pigmentation
• Genodermatoses